Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · Need to know. Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes. Get informed.
New prototype therapy may repair IPF lung scarring by …
Apr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
Zelasudil wins FDA orphan drug status as IPF treatment candidate
Aug 25, 2023 · Novel oral therapy seen to lessen scarring in preclinical studies. Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA).
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · Among people with progressive PF, six-month treatment with the 60 mg dose of BMS-986278 led to a 69% relative reduction in the rate of lung function decline compared with placebo, as measured by the percent predicted forced vital capacity (ppFVC).
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial.
Pliant Therapeutics accelerates development of bexotegrast for IPF
Apr 5, 2024 · Pliant Therapeutics’ Phase 2b BEACON-IPF trial testing bexotegrast, an investigational oral treatment, in people with idiopathic pulmonary fibrosis (IPF) is now a pivotal, adaptive Phase 2b/3 trial.
Pulmonary Fibrosis News Forums
Healthcare Questions. This is a space for the community to discuss healthcare resources and information. Supplements and Non-traditional Management of PF Diagnosis Information and General Questions Upcoming Medical Appointments: Q&As Coronavirus (COVID-19) and Pulmonary Fibrosis. 1 week, 2 days ago.
FDA clears Phase 2 trial of GRI-0621 NKT-cell targeted therapy
Dec 1, 2023 · The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2 trial of its investigational natural killer T-cell (NKT)-targeted therapy, GRI-0621, in people with idiopathic pulmonary fibrosis (IPF).
IPF treatment ISM001-055 safe, improves lung function, data show
Oct 11, 2024 · Insilico Medicine ’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial.
Clinical studies of IPF treatment INS018_055 advance in US, China
Jul 12, 2024 · A Phase 2a clinical trial testing the safety of treatment candidate INS018_055 among idiopathic pulmonary fibrosis (IPF) patients in the U.S. is still seeking participants, while a parallel trial in China has now completed enrollment.